Cancer in Turkey as well as all over the world also continues to be a major health problem. In developed countries, there are 6 million cancer cases and 2.9 million cancer-related deaths every year. In less developed countries, the number of cases is 33% higher and the number of deaths is 83% higher, as many cancer patients do not even have access to basic treatment. In order to reduce the economic burden in the field of health and to enable patients to reach more effective treatments, "theranostic" approaches that are based on personalized treatment and that provide a transition from traditional medicine to a modern and original medical understanding gain importance. There is a need to develop new diagnostic kits, treatment methods and vaccines for endemic and pandemic infections (eg COVID-19) that have a high impact on public health such as cancer.
Ankara Innovative Teranostic Development Center (AnkaTheraHub) is established to increase the capacity of SMEs working on high-tech healthcare needs and to improve applied research in the field of cancer and infectious diseases. AnkaTheraHub conducted by Ankara University (A.Ü.), A.Ü. Institute of Cancer Research, Health Industry Employers Association of Turkey and Ankara University Technology Transfer Office, Ministry of Health, Turkey Pharmaceuticals and Medical Devices Agency, Ankara Development Agency, Technology Development Foundation of Turkey, OSTİM Medical Cluster and supported by the Turkish Medical Oncology Association.
Turkey, described in magnitude to 8 billion euros in 2016, 16th in the world in the pharmaceutical industry, it ranks 6th in Europe. However, SMEs having problems in manufacturing in accordance with European and US standards need technical and financial support in order to be competitive. AnkaTheraHub, which will increase the product development and innovation capacities of SMEs, aims to develop innovative diagnostic and treatment products.
In addition to the incubation and accelerator services provided to SMEs, AnkaTheraHub also offers common use for 8 different technical units that will be equipped with high-tech machinery and equipment. Innovative research on cancer at AnkaTheraHub will be brought to the prototype stage; It will be commercialized with the support of technical infrastructure, model quality management system, clinical trial planning and legal approval procedure.
SMEs benefit from incubation center training activities within AnkaTheraHub; clinical trial planning and legal approval procedure support and model quality management system support. Management training and technical training are planned to increase the capacity of the center. It is envisaged that the supported organizations will create 40 research jobs and 10 innovative businesses will be established. Establishment of 6 research partnerships to develop innovative products in line with the services of the center; Development and prototyping of 22 innovative products; It is aimed to successfully commercialize 2 products. As a result of 12 national and 4 international patent applications to be made, it is expected to obtain at least 5 national and 2 internationally approved patents.
AnkaTheraHub, which will serve as a technical infrastructure and assistance center to support R&D and commercialization activities of SMEs working in the field of cancer and viral diseases, will enable patients to access high-tech diagnosis and treatment products at affordable costs with competitive products.
|Project Owner||Implementation Area||Detailed Information|